It is not news that cannabis-based medicines have been used for millennia around the world in the treatment of conditions and diseases such as chronic pain; epilepsy; neuropsychiatric disorders; nausea and vomiting related to chemotherapy; symptoms associated with autistic spectrum disorder; amyotrophic lateral sclerosis; rheumatoid arthritis, among others. However, this topic has been the subject of recent discussions due to the progressive dissemination of scientific data proving the efficacy and safety of their uses. New scientific research and clinical studies are expected, not to mention the revision/alteration of legislation in some countries so that the cultivation, production, commercialization and use of cannabis-based medicines becomes more viable and comprehensive.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, June 2: Unitary Patent System Launches; WIPO Hosts IP and Sustainability Conference; and the USPTO Extends its Climate Change Program
- Iancu Agrees Key USPTO ANPRM Proposals Should be Handled by Congress
- The Intersection of NILS, NFTS, AI Creations, Big Data, and the Metaverse
- Understanding IP Matters: AI Bots, Creators, and Copyright — Learning to Live Together
- Clause 8: Joff Wild on Founding IAM for Chief IP Officers and EU Commission’s Anti-SEP Crusade
Recent Posts
- Other Barks & Bites for Friday, June 2: Unitary Patent System Launches; WIPO Hosts IP and Sustainability Conference; and the USPTO Extends its Climate Change Program
- Iancu Agrees Key USPTO ANPRM Proposals Should be Handled by Congress
- The Intersection of NILS, NFTS, AI Creations, Big Data, and the Metaverse
- Understanding IP Matters: AI Bots, Creators, and Copyright — Learning to Live Together
- Clause 8: Joff Wild on Founding IAM for Chief IP Officers and EU Commission’s Anti-SEP Crusade